AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Subscribe To Our Newsletter & Stay Updated